Compare Dr. Reddys with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs TORRENT PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB TORRENT PHARMA DR. REDDYS LAB/
TORRENT PHARMA
 
P/E (TTM) x 16.8 54.4 30.9% View Chart
P/BV x 3.2 6.5 49.4% View Chart
Dividend Yield % 0.7 0.8 93.2%  

Financials

 DR. REDDYS LAB   TORRENT PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
TORRENT PHARMA
Mar-18
DR. REDDYS LAB/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs2,8751,550 185.5%   
Low Rs1,8881,144 165.1%   
Sales per share (Unadj.) Rs930.2354.7 262.3%  
Earnings per share (Unadj.) Rs117.440.1 293.0%  
Cash flow per share (Unadj.) Rs185.864.2 289.2%  
Dividends per share (Unadj.) Rs20.0014.00 142.9%  
Dividend yield (eoy) %0.81.0 80.8%  
Book value per share (Unadj.) Rs844.4273.1 309.2%  
Shares outstanding (eoy) m166.07169.22 98.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.63.8 67.4%   
Avg P/E ratio x20.333.6 60.4%  
P/CF ratio (eoy) x12.821.0 61.1%  
Price / Book Value ratio x2.84.9 57.2%  
Dividend payout %17.034.9 48.8%   
Avg Mkt Cap Rs m395,496227,897 173.5%   
No. of employees `00022.014.7 149.4%   
Total wages/salary Rs m33,56211,353 295.6%   
Avg. sales/employee Rs Th7,032.84,083.0 172.2%   
Avg. wages/employee Rs Th1,527.9772.3 197.8%   
Avg. net profit/employee Rs Th887.7461.3 192.4%   
INCOME DATA
Net Sales Rs m154,48260,021 257.4%  
Other income Rs m3,3752,988 112.9%   
Total revenues Rs m157,85763,009 250.5%   
Gross profit Rs m31,78213,493 235.6%  
Depreciation Rs m11,3484,086 277.7%   
Interest Rs m8893,085 28.8%   
Profit before tax Rs m22,9209,310 246.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8582,529 152.6%   
Profit after tax Rs m19,5006,781 287.6%  
Gross profit margin %20.622.5 91.5%  
Effective tax rate %16.827.2 62.0%   
Net profit margin %12.611.3 111.7%  
BALANCE SHEET DATA
Current assets Rs m111,10152,623 211.1%   
Current liabilities Rs m58,97352,022 113.4%   
Net working cap to sales %33.71.0 3,367.1%  
Current ratio x1.91.0 186.2%  
Inventory Days Days79120 66.4%  
Debtors Days Days9476 123.6%  
Net fixed assets Rs m101,24585,016 119.1%   
Share capital Rs m830846 98.1%   
"Free" reserves Rs m139,40645,376 307.2%   
Net worth Rs m140,23646,222 303.4%   
Long term debt Rs m22,00041,115 53.5%   
Total assets Rs m224,656142,432 157.7%  
Interest coverage x26.84.0 666.5%   
Debt to equity ratio x0.20.9 17.6%  
Sales to assets ratio x0.70.4 163.2%   
Return on assets %9.16.9 131.0%  
Return on equity %13.914.7 94.8%  
Return on capital %14.914.2 105.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67314,580 608.2%   
Fx outflow Rs m19,1043,600 530.7%   
Net fx Rs m69,56910,980 633.6%   
CASH FLOW
From Operations Rs m28,7048,942 321.0%  
From Investments Rs m-7,727-47,070 16.4%  
From Financial Activity Rs m-21,32634,174 -62.4%  
Net Cashflow Rs m-314-3,655 8.6%  

Share Holding

Indian Promoters % 25.5 71.5 35.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 7.0 76.9%  
FIIs % 35.3 12.6 280.2%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 8.8 173.9%  
Shareholders   75,885 26,511 286.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  PFIZER  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 15, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - WYETH LTD COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS